Is low-dose tafenoquine combined with dihydroartemisinin-piperaquine a potential risk factor for Plasmodium vivax resistance to 8-aminoquinolines?

Affiliations

Free article

Comment

Temi Lampejo. Lancet Microbe. 2022 Jul.

Free article

. 2022 Jul;3(7):e477.

doi: 10.1016/S2666-5247(22)00113-6. Epub 2022 Apr 26.

¹ Department of Infection Sciences, King's College Hospital, London, UK. Electronic address: temi.lampejo@nhs.net.

No abstract available

Conflict of interest statement

I declare no competing interests.

Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
Stone W, Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, Sacko A, Keita S, Dicko OM, Diallo M, Maguiraga SO, Samake S, Attaher O, Lanke K, Ter Heine R, Bradley J, McCall MBB, Issiaka D, Traore SF, Bousema T, Drakeley C, Dicko A. Stone W, et al. Lancet Microbe. 2022 May;3(5):e336-e347. doi: 10.1016/S2666-5247(21)00356-6. Epub 2022 Mar 23. Lancet Microbe. 2022. PMID: 35544095 Free PMC article. Clinical Trial.